Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

• Status: Active, not recruiting
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Lenvatinib

Criteria

Inclusion Criteria:

• Age >/= 18 years

• Initiating cabozantinib for progressive DTC, MTC, malignant PH or PGs or lenvatinib for progressive DTC or MTC as determined by patient's endocrinologist

• ECOG performance status 0-2

• Able to communicate in English or Spanish

• Able to provide informed consent

Exclusion Criteria:

• Active participation in any weight reduction program including use of drugs used for weight loss

• Inability to ambulate without assistance (e.g. cane, walker)

• Multiple Endocrine Neoplasia (MEN) 2B (due to differences in body habitus)

• Patients unwilling or unable to comply with the protocol.

• Use of chronic (>3 months consecutively) non-physiological (15 mg/m² hydrocortisone equivalent) doses of glucocorticoids

• Non-English speaking PH and PG patients